Trefoil Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Dose Escalation TTHX1114 Ophthalmic Solution
Phase 1
Completed
- Conditions
- Corneal Epithelial Degeneration
- Interventions
- Drug: TTHX1114(NM141) Ophthalmic Solution
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Trefoil Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05769920
- Locations
- 🇺🇸
Trefoil Clinical Site #132, Cypress, California, United States
A Safety and Efficacy Trial of TTHX1114 in People With CED
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Trefoil Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04812067
- Locations
- 🇺🇸
Trefoil Study Site, Washington, Missouri, United States
TTHX1114(NM141) in Combination With DWEK/DSO
Phase 2
Completed
- Conditions
- Fuchs' Endothelial DystrophyFuchs DystrophyFuchs
- Interventions
- Drug: TTHX1114(NM141)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Trefoil Therapeutics, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04676737
- Locations
- 🇺🇸
Trefoil Investigational Site 124, Long Beach, California, United States
🇺🇸North Bay Eye Associates, Petaluma, California, United States
🇺🇸Trefoil Investigational Site 123, Deerfield Beach, Florida, United States
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Phase 1
Completed
- Conditions
- Corneal Endothelial DystrophyFuchs Endothelial Corneal DystrophyPseudophakic Bullous KeratopathyEndothelial Dysfunction
- Interventions
- Other: Vehicle (placebo)Drug: TTHX1114(NM141)
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Trefoil Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04520321
- Locations
- 🇺🇸
North Bay Eye Associates, Inc., Petaluma, California, United States
🇺🇸Levenson Eye Associates, Inc, Jacksonville, Florida, United States
🇺🇸Chicago Corneal Consultants, Hoffman Estates, Illinois, United States
News
No news found